Obesity drugs show early promise against the hormonal disorder PMOS, giving a suffering family hope
Charlotte Touzalin was still a young teenager when she began struggling with weight gain, abnormal periods and unwanted facial hair—the same puzzling symptoms that plagued her mom for decades and that no doctor could piece together.
Obesity drugs show early promise as potential treatments for the hormonal disorder PMOS, giving hope to families affected by the condition. Charlotte Touzalin, an 18-year-old college student from Colorado, and her mother Anne Schultz were recently diagnosed with PMOS after struggling with weight gain, abnormal periods, and unwanted facial hair.
PMOS, formerly known as polycystic ovary syndrome, affects one in eight women worldwide and is characterized by insulin resistance, high levels of testosterone, and irregular ovulation. Unlike Schultz, Touzalin is now receiving treatment through a study testing GLP-1 drugs, which have shown promise in improving insulin resistance, hormone balance, and ovulation.
Dr. Melanie Cree, who has led studies testing GLP-1 drugs for PMOS, reported that eight out of 11 participants in her study lost at least 10% of their body weight, with a median loss of about 42 pounds. Six women also experienced more regular periods, and four of them went on to have monthly periods. Both Touzalin and her mother have experienced improvements in their symptoms, with Touzalin feeling more like a "normal person" after losing weight and normalizing her periods.
Despite these promising results, GLP-1 drugs are not currently approved for treating PMOS, and insurance coverage remains a challenge for many patients.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
